Hazel Dunbar
Overview
Explore the profile of Hazel Dunbar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
41
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dunbar H, Hawthorne I, Tunstead C, Dunlop M, Volkova E, Weiss D, et al.
Eur J Immunol
. 2024 Nov;
55(1):e202451205.
PMID: 39502000
Enhancing mesenchymal stromal cell (MSC) therapeutic efficacy through licensing with proinflammatory cytokines is now well established. We have previously shown that macrophage migration inhibitory factor (MIF)-licensed MSCs exerted significantly enhanced...
2.
Tunstead C, Volkova E, Dunbar H, Hawthorne I, Bell A, Crowe L, et al.
Mol Ther
. 2024 Aug;
32(10):3422-3432.
PMID: 39108095
Clinical trials investigating the potential of mesenchymal stromal cells (MSCs) for the treatment of inflammatory diseases, such as acute respiratory distress syndrome (ARDS), have been disappointing, with less than 50%...
3.
Dunbar H, Hawthorne I, English K
Mol Ther
. 2024 Jun;
32(7):2047-2049.
PMID: 38906151
No abstract available.
4.
Dunbar H, Hawthorne I, Tunstead C, McNamee E, Weiss D, Armstrong M, et al.
Cytotherapy
. 2024 May;
26(10):1245-1251.
PMID: 38819366
Background: Trained immunity results in long-term immunological memory, provoking a faster and greater immune response when innate immune cells encounter a secondary, often heterologous, stimulus. We have previously shown that...
5.
Dunbar H, Hawthorne I, English K
Thorax
. 2024 Apr;
79(8):698-699.
PMID: 38575316
No abstract available.
6.
Dunbar H, Hawthorne I, McNamee E, Armstrong M, Donnelly S, English K
FASEB J
. 2024 Mar;
38(6):e23576.
PMID: 38530238
High level expression of the pro-inflammatory cytokine macrophage migration inhibitory factor (MIF) has been associated with severe asthma. The role of MIF and its functional promotor polymorphism in innate immune...
7.
Hawthorne I, Dunbar H, Tunstead C, Schorpp T, Weiss D, Rolandsson Enes S, et al.
Mol Ther
. 2023 Sep;
31(11):3243-3258.
PMID: 37735872
Current asthma therapies focus on reducing symptoms but fail to restore existing structural damage. Mesenchymal stromal cell (MSC) administration can ameliorate airway inflammation and reverse airway remodeling. However, differences in...
8.
Dunbar H, Hawthorne I, Tunstead C, Armstrong M, Donnelly S, English K
FASEB J
. 2023 Jul;
37(8):e23072.
PMID: 37498233
Macrophage migration inhibitory factor (MIF) expression is controlled by a functional promoter polymorphism, where the number of tetranucleotide repeats (CATT ) corresponds to the level of MIF expression. To examine...
9.
Gallagher C, Mac Mahon J, ONeill C, Cassidy F, Dunbar H, De Barra C, et al.
J Invest Dermatol
. 2022 Dec;
143(6):1094-1097.e2.
PMID: 36516909
No abstract available.
10.
Dunbar H, Weiss D, Rolandsson Enes S, Laffey J, English K
Cells
. 2021 Nov;
10(11).
PMID: 34831203
Recent clinical trials of mesenchymal stromal cell (MSC) therapy for various inflammatory conditions have highlighted the significant benefit to patients who respond to MSC administration. Thus, there is strong interest...